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Abstract. Here we report a documented case of congenital transmission of Trypanosoma cruzi from a Bolivian
mother with chronic Chagas disease living in Spain. The serology and blood nested polymerase chain reaction (PCR)
were positive for the mother, and amastigote forms were observed in histopathological study of the placenta and
umbilical cord. Direct examination, culture, and nested PCR were positive in the blood of the neonate. At the age of 8
days, the neonate began treatment with 5–7.5 mg/kg/day of benznidazol, which was continued for 60 days. Direct
examination, blood culture, and nested PCR were negative to T. cruzi 20 days after the start of treatment and remained
negative 4 and 7 months thereafter. Serological tests were negative at 4 months. To detect congenital infection and
initiate early treatment of infected newborns, protocols are required to detect Chagas disease in pregnant women who
migrate from endemic to non-endemic areas.
INTRODUCTION
Chagas disease or American trypanosomiasis is a widely
distributed endemic zoonosis in Central and South America,
where ∼11 million people are infected and an estimated 100
million people are at risk of infection. The disease is caused
by the protozoan Trypanosoma cruzi and is usually consid-
ered as one affecting poor people in rural communities. In
endemic areas, T. cruzi is transmitted mainly by triatomine
insect vectors, which release excreta infected with the parasite
into lacerated skin or mucosa. In addition to insect transmis-
sion, the infection may also occur through blood transfusion
of whole blood or blood derivatives, congenital transmission
from infected mothers, organ transplantation (kidney, heart,
bone marrow, and others), and accidental contamination in
the laboratory.1 Infection occurs to a lesser extent by oral
transmission through food, such as meat, sugar cane juice, and
fruit juice, contaminated with infected triatomines or their
dejections.1,2
At present, Chagas disease is a potential public health
problem in Spain as a result of the increasing number of
migrants from countries in which it is endemic. To our knowl-
edge, a case of asymptomatic congenital transmission has
been reported in Europe in a 5-year-old Latin American child
living in Romania who had never traveled to an endemic
area.3 Another congenital case has recently been diagnosed in
a 2-year-old child in Barcelona (J. Muñoz and others, unpub-
lished data). Here we report the first case of congenital Cha-
gas disease transmission diagnosed in a neonate in Europe
(Spain). We studied T. cruzi infection in the mother and the
neonate, and a parasitological and serological longitudinal
follow-up was performed on the child to monitor response to
treatment.
CASE REPORT
A 28-year-old expectant Bolivian mother with chronic Cha-
gas disease informed physicians of her condition at delivery.
The patient was asymptomatic, and anamnesis established
that she had been infected at the age of 6 and diagnosed and
treated at the age of 22 in Bolivia. The woman had two other
children, 10 and 12 years of age, who lived in Bolivia and
whose clinical condition was unknown.
The neonate was delivered at 37 weeks of gestation by
caesarean section. Vaginal and rectal cultures for the mother
were positive for Streptococus agalactiae, and she was treated
with endovenous ampicillin during dilation. Caesarean deliv-
ery was required because attempts to induce birth failed. The
newborn was a boy weighing 2.905 kg. Preliminary examina-
tion of the infant detected no complications. The mother
nursed the neonate, who showed a satisfactory evolution.
Splenomegaly, hyperbilirubinemia, and encephalitis were not
detected, and additional hematological and biochemical pa-
rameters were normal.
After delivery, the mother and the newborn were immedi-
ately examined for Chagas disease using parasitological and
serological methods. The serological diagnosis of T. cruzi in-
fection in sera was performed using a commercial ELISA
with recombinant antigens (BioELISA Chagas; Biokit S.A.,
Lliça d’Amunt, Barcelona, Spain) and a non-commercial con-
ventional ELISA with a whole lysate antigen obtained from
epimastigotes of T. cruzi I strain. The bands recognized by the
sera from mother and child were studied by Western blot
(WB) analysis with the same antigen used in the conventional
ELISA. A nested polymerase chain reaction (PCR) was per-
formed following the standard technique (external primers
TCZ1 and TCZ2 and internal primers TCZ3 and TCZ4,
which amplify a DNA fragment of 149 bp of a repetitive
sequence of nuclear DNA of 195 bp).4
A blood sample from the mother was taken for laboratory
diagnosis of Chagas disease. Microscopic observation of
blood and culture in NNN medium were negative, and nested
PCR was positive for T. cruzi DNA. Maternal seroreactivity
to T. cruzi antigens was positive by ELISA and WB analyses
(Table 1; Figure 1). Histopathological study of the placenta
and umbilical cord was performed, and T. cruzi amastigote
forms were observed in both samples (Figures 2 and 3).
Trypomastigote forms in the blood stream were detected
using the microhematocrit concentration technique. The
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parasite was isolated by blood culture in NNN and T. cruzi
DNA was detected by nested PCR. The strain was identified
as T. cruzi I. Serological study by ELISA showed high levels
of specific antibodies (Table 1), and the WB pattern of bands
was identical in the newborn and mother (Figure 1).
Once congenital infection was confirmed, the neonate was
treated with benznidazol (5–7.5 mg/kg/day) every 12 hours for
60 days. Parasitological and serological follow-up was per-
formed at 20 days and 4 and 7 months after beginning treat-
ment. Parasitemia, monitored by nested PCR and blood cul-
ture, was negative at day 20 after the start of treatment and
remained negative at 4 and 7 months. At 4 months, ELISA
tests were negative (Table 1), and the WB pattern showed a
reduction in the number and intensity of bands (Figure 1).
Clinical, hematological, and biochemical follow-up of the in-
fant was performed for 12 months, during which time values
were normal, and the child remained clinically asymptomatic.
The infant showed good tolerance to treatment and normal
development.
DISCUSSION
Chagas disease enters the chronic phase 2–4 months after
the acute clinical symptoms disappear and generally develops
FIGURE 1. Trypanosoma cruzi antigen polypeptide recognition of
sera from mother at delivery (m) and newborn at 1 day (a), 20 days
(b), and 4 months (c) after initiating anti-parasitic treatment. Whole
antigen from T. cruzi epimastigotes was electrophoretically separated
in sodium dodecyl sulphate-polyacrylamide gels (12%) and trans-
ferred to nitrocellulose sheets. Immunoreaction was performed with
sera at 1:50 dilution, and bound immunoglobulins were detected with
protein A peroxidase conjugate (Sigma) at 1:1,000 dilution.
FIGURE 2. Histologic section of the extra-placental membranes,
stained with hematoxylin-eosin, showing amastigotes of T. cruzi
(H&E, ×60).
TABLE 1





Time after beginning treatment
20 days 4 months 7 months
Microscopy Negative Positive Negative Negative Negative
Culture Negative Positive Negative Negative Negative
Nested PCR Positive Positive Negative Negative Negative
ELISA R* 6.6 6.2 5.8 0.5 0.2
ELISA W† 61 51 36 10 7
* ELISA R (recombinant antigen, BioELISA Chagas, Biokit); cut-off  1.
† ELISA W (whole antigen, in house): cut-off  20.
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with a long period of clinical latency called the indeterminate
form, which lasts 10–30 years or throughout life.1 Infected
pregnant women are usually asymptomatic, and the condi-
tions and mechanisms of congenital transmission remain
largely unknown. In endemic areas, seroprevalence in preg-
nant women may be as high as 81%, and the probability of
congenital transmission in children of chagasic mothers
ranges from < 1% to 10%, depending on the geographic
area.5 Congenital transmission can occur in any phase of the
maternal disease, but the risk is greater during the acute
phase when parasitemia is intense and persistent. This period,
however, is short, which might explain the small number of
cases of transmission reported during this phase.6,7 In the
chronic stage, there is intermittent parasitemia, and therefore,
transmission may also occur, with rates estimated at around
1.6%.8,9 Indeed, the number of parasites in infected mothers,
the strains involved, placental factors, and/or maternal immu-
nity may determine congenital transmission of T. cruzi.10 Risk
factors for the transmission of congenital Chagas disease and
the pathophysiological and clinical features of congenital dis-
ease have been explained in several reports8,11–13 The diag-
nosis of congenital Chagas disease in the newborn is some-
times difficult because of low parasitemia and the persistence
of positive serology, caused by the presence of antibodies
transmitted to the neonate by the mother. In our case, the
mother showed amastigote forms in the placenta and umbili-
cal cord. Confirmation of T. cruzi in blood was positive only
by nested PCR of the buffy coat, whereas the conventional
parasitological techniques in blood were negative. Placental
infection is not always synonymous with fetal infection,7 and
no information is available on correlations between low par-
asitemia, detected by PCR, in the mother and the probability
of fetal infection. In the case reported here, the detection of
parasite by PCR in maternal blood together with the presence
of parasite in placenta was associated with fetal infection.
Trypanosoma cruzi infection was diagnosed in the neonate
by observation of trypomastigotes in smears from the buffy
coat fraction (microhematocrit concentration) and by positive
culture, thereby indicating the presence of circulating para-
sites. Twenty days after the neonate started treatment, direct
examination, culture, and PCR were negative and remained
negative during the follow-up.
ELISA detected high levels of IgG-specific antibodies in
the newborn and in the mother. Nevertheless, high levels of
IgG in the former has low predictive value of congenital
transmission because of the passive transfer of maternal IgG
antibodies, which could be present for up to 7 months in the
non-infected child.14 Comparison of the immunologic profile
of the mother and child, detected by WB analysis, allows
differentiation between passively transmitted maternal anti-
bodies and those newly synthesized in the infant, which are
used in early postnatal diagnosis of congenital toxoplasmo-
sis.15 In our case, no differences in the band pattern of the
sera from the mother and newborn were detected after de-
livery, and no new bands were recognized by child sera during
the follow-up period. Therefore, neonate production of anti-
bodies could not be appreciated.
Microscopic observation of bloodstream trypomastigotes
and/or culture of the buffy coat fraction of blood samples
using the microhematocrit concentration technique are com-
monly used to diagnose congenital infection and are highly
sensitive when parasitemia is high, as in the case reported
here. In contrast, when parasitemia is low, conventional para-
sitological and serological techniques are not efficient enough
to provide early diagnosis of congenital Chagas disease. How-
ever, PCR is an easy, rapid, and sensitive diagnostic method
that requires only a small amount of blood,16 although un-
usual false-positive results have been described.17 In addition,
this technique can be used to monitor parasitemia in infants
after treatment.17,18
Early diagnosis of T. cruzi infection is essential for the
rapid administration of anti-parasitic therapy. Studies on ni-
furtimox or benznidazol treatments show that the cure rate
depends on the speed with which treatment is initiated. Most
infants treated early test negative when examined 6 months to
2 years after starting treatment.12,17,18 The data obtained in
our study are consistent with these results and show that
treatment is effective when started during the first months of
life.
Given the increasing number of women of fertile age mi-
grating to Spain from regions with endemic Chagas disease,
new cases of congenital transmission may occur. To increase
the early detection of congenitally infected babies and thus
facilitate their early treatment, we recommend screening for
Chagas disease in pregnant women from endemic areas and
the establishment of diagnostic protocols to detect the infec-
tion in the neonate.
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